{
    "clinical_study": {
        "@rank": "4984", 
        "arm_group": [
            {
                "arm_group_label": "metformin and  healthy habits program", 
                "arm_group_type": "Active Comparator", 
                "description": "1 gr per day.  (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months."
            }, 
            {
                "arm_group_label": "Conjugated Linoleic Acid and healthy habits", 
                "arm_group_type": "Experimental", 
                "description": "Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months."
            }, 
            {
                "arm_group_label": "Placebo and healthy habits program", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical trial is to examine the effects of conjugated linoleic acid\n      (CLA) vs metformin along with an intervention program with healthy habits on body\n      composition, weight, M value in CLAMP and clinical laboratory values, as well as molecular\n      and genetic changes in obese children.\n\n      Patients from the pediatric service of the Hospital from 8 to 18 years old with a body mass\n      index  \u2265 Pc 95 and 35kg/m2 are randomized to either interventional group for 4 months."
        }, 
        "brief_title": "Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients of both sexes between 8 and 18 years old\n\n          -  Pc BMI \u2265 95 and <35kg/m2,\n\n          -  No endocrine diseases, including diabetes mellitus\n\n          -  No systemic diseases\n\n          -  No genetic diseases\n\n          -  No pharmacological treatment affecting lipid metabolism or glucose\n\n          -  No history of acute or prolonged immobilization\n\n          -  Normal aminotransferases\n\n          -  Signed Informed consent and assent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063802", 
            "org_study_id": "DI/11/311/04/108"
        }, 
        "intervention": [
            {
                "arm_group_label": "metformin and  healthy habits program", 
                "description": "total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Conjugated Linoleic Acid and healthy habits", 
                "description": "total dose: 3gr/d\u00eda(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.", 
                "intervention_name": "Conjugated Linoleic Acid", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo and healthy habits program", 
                "description": "Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "metformin and  healthy habits program", 
                    "Conjugated Linoleic Acid and healthy habits", 
                    "Placebo and healthy habits program"
                ], 
                "intervention_name": "Healthy habits program", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pediatric obesity", 
            "conjugated linoleic acid", 
            "CLA", 
            "metformin"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "email": "gngaribay@hotmail.com", 
                "last_name": "Nayely G Garibay, Pediatrician", 
                "phone": "+52 (55) 59-48-26-37"
            }, 
            "contact_backup": {
                "email": "mayibe2609@gmail.com", 
                "last_name": "Mayra A Bustos, Doctor", 
                "phone": "+52 7773406509"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico", 
                    "country": "Mexico", 
                    "state": "Distrito Federal", 
                    "zip": "06726"
                }, 
                "name": "General Hospital of Mexico"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients", 
        "overall_contact": {
            "email": "jogonzalez@silanes.com.mx", 
            "last_name": "Jorge A Gonzalez, Director", 
            "phone": "521 (55)54883761", 
            "phone_ext": "3761"
        }, 
        "overall_contact_backup": {
            "email": "Yromero@silanes.com.mx", 
            "last_name": "Yulia Romero, Coordinator", 
            "phone": "521 (55)54883700", 
            "phone_ext": "3777"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital General de M\u00e9xico", 
                "last_name": "Nayely G Garibay, Pediatrician", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital General de M\u00e9xico", 
                "last_name": "Gloria E Queipo, M.Specialist", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in body mass index at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in body fat mass at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in lean body mass at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063802"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in clinical laboratory values at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in M Value in CLAMP at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in muscle tissue transcriptome at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in adipose tissue transcriptome at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in inflammatory cytokines al 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in the phosphorylation of the insulin receptor in muscle tissue at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in the phosphorylation of the insulin receptor in adipocytes at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Change in activation status of proteins involved in insulin signaling of myocytes cDNA at 4 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 4 months"
            }, 
            {
                "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 months"
            }
        ], 
        "source": "Laboratorios Silanes S.A. de C.V.", 
        "sponsors": {
            "collaborator": {
                "agency": "Hospital General de Mexico", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Laboratorios Silanes S.A. de C.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}